Sana Biotechnology Inc. (NASDAQ: SANA) announced that preclinical data from its CD19-directed in vivo CAR T product candidate SG293 will ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE